Recent progress in sodium channel modulators for pain.

Voltage-gated sodium channels (Navs) are an important family of transmembrane ion channel proteins and Nav drug discovery is an exciting field. Pharmaceutical investment in Navs for pain therapeutics has expanded exponentially due to genetic data such as SCN10A mutations and an improved ability to establish an effective screen sequence for example IonWorks Barracuda®, Synchropatch® and Qube®. Moreover, emerging clinical data (AZD-3161, XEN402, CNV1014802, PF-05089771, PF-04531083) combined with recent breakthroughs in Nav structural biology pave the way for a future of fruitful prospective Nav drug discovery.

[1]  William A. Catterall,et al.  Crystal structure of a voltage-gated sodium channel in two potentially inactivated states , 2012, Nature.

[2]  M. Noda,et al.  Structure and function of sodium channel. , 1987, Journal of receptor research.

[3]  W. Catterall,et al.  THE CRYSTAL STRUCTURE OF A VOLTAGE-GATED SODIUM CHANNEL , 2011, Nature.

[4]  S. Dib-Hajj,et al.  Gain-of-function Nav1.8 mutations in painful neuropathy , 2012, Proceedings of the National Academy of Sciences.

[5]  John N. Wood,et al.  SCN9A Mutations in Paroxysmal Extreme Pain Disorder: Allelic Variants Underlie Distinct Channel Defects and Phenotypes , 2006, Neuron.

[6]  F. Blaney,et al.  Structural Determinants of Drugs Acting on the Nav1.8 Channel* , 2009, Journal of Biological Chemistry.

[7]  S. Dib-Hajj,et al.  Sodium channels in normal and pathological pain. , 2010, Annual review of neuroscience.

[8]  O. McManus.  HTS assays for developing the molecular pharmacology of ion channels. , 2014, Current opinion in pharmacology.

[9]  S. Dib-Hajj,et al.  Gain of function NaV1.7 mutations in idiopathic small fiber neuropathy , 2012, Annals of neurology.

[10]  T. Cummins,et al.  Nav1.7 mutations associated with paroxysmal extreme pain disorder, but not erythromelalgia, enhance Navβ4 peptide‐mediated resurgent sodium currents , 2011, The Journal of physiology.

[11]  S. Dib-Hajj,et al.  Two tetrodotoxin‐resistant sodium channels in human dorsal root ganglion neurons , 1999, FEBS letters.

[12]  Clare London,et al.  Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. , 2007, Biochemistry.

[13]  E. Campbell,et al.  Atomic structure of a voltage-dependent K+ channel in a lipid membrane-like environment , 2007, Nature.

[14]  B. Ding,et al.  Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia , 2004, Journal of Medical Genetics.

[15]  X. Zhang,et al.  Gain-of-function mutations in SCN11A cause familial episodic pain. , 2013, American journal of human genetics.

[16]  D. Henze,et al.  Recent Advances Toward Pain Therapeutics , 2011 .

[17]  B. Bean,et al.  Role of Tetrodotoxin-Resistant Na+ Current Slow Inactivation in Adaptation of Action Potential Firing in Small-Diameter Dorsal Root Ganglion Neurons , 2003, The Journal of Neuroscience.

[18]  A. Gibbs,et al.  Analysis of the Structural and Molecular Basis of Voltage-sensitive Sodium Channel Inhibition by the Spider Toxin Huwentoxin-IV (μ-TRTX-Hh2a) , 2013, The Journal of Biological Chemistry.

[19]  C. Gibbons,et al.  Diagnosis and Treatment of Pain in Small-fiber Neuropathy , 2011, Current pain and headache reports.

[20]  Michael P. Eastwood,et al.  Atomic-level simulation of current–voltage relationships in single-file ion channels , 2013, The Journal of general physiology.

[21]  Kresten Lindorff-Larsen,et al.  Principles of conduction and hydrophobic gating in K+ channels , 2010, Proceedings of the National Academy of Sciences.

[22]  James O. Jackson,et al.  The Tarantula Toxins ProTx-II and Huwentoxin-IV Differentially Interact with Human Nav1.7 Voltage Sensors to Inhibit Channel Activation and Inactivation , 2010, Molecular Pharmacology.

[23]  M. Hayden,et al.  Treatment of Nav1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker , 2012, PAIN.

[24]  Martin Koltzenburg,et al.  ProTx-II, a Selective Inhibitor of NaV1.7 Sodium Channels, Blocks Action Potential Propagation in Nociceptors , 2008, Molecular Pharmacology.

[25]  Peter Nürnberg,et al.  A de novo gain-of-function mutation in SCN11A causes loss of pain perception , 2013, Nature Genetics.

[26]  W. Catterall,et al.  Molecular mechanisms of neurotoxin action on voltage-gated sodium channels. , 2000, Biochimie.

[27]  J. Schulz,et al.  Butyl 2-(4-[1.1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate, a potent sodium channel blocker for the treatment of neuropathic pain. , 2007, Bioorganic & medicinal chemistry letters.

[28]  W. Catterall,et al.  Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Cecilia Farre,et al.  Renaissance of ion channel research and drug discovery by patch clamp automation. , 2010, Future medicinal chemistry.

[30]  J. Wood,et al.  GTP up‐regulated persistent Na+ current and enhanced nociceptor excitability require NaV1.9 , 2008, The Journal of physiology.

[31]  M. D. de Groot,et al.  Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels , 2013, Proceedings of the National Academy of Sciences.

[32]  S. Waxman,et al.  The roles of sodium channels in nociception: Implications for mechanisms of pain , 2007, PAIN.

[33]  Markéta Bébarová,et al.  Advances in patch clamp technique: towards higher quality and quantity. , 2012, General physiology and biophysics.

[34]  S. Dib-Hajj,et al.  Gain-of-function mutations in sodium channel Na(v)1.9 in painful neuropathy. , 2014, Brain : a journal of neurology.

[35]  Hussain Jafri,et al.  An SCN9A channelopathy causes congenital inability to experience pain , 2006, Nature.

[36]  H. Takeshima,et al.  Expression of functional sodium channels from cloned cDNA , 1986, Nature.

[37]  Jeffrey J Clare,et al.  Targeting ion channels for drug discovery. , 2010, Discovery medicine.

[38]  M. D. de Groot,et al.  Subtype‐selective targeting of voltage‐gated sodium channels , 2009, British journal of pharmacology.

[39]  G. King,et al.  Discovery of a selective NaV1.7 inhibitor from centipede venom with analgesic efficacy exceeding morphine in rodent pain models , 2013, Proceedings of the National Academy of Sciences.

[40]  M. Bednarek,et al.  Potency optimization of Huwentoxin-IV on hNav 1.7: A neurotoxin TTX-S sodium-channel antagonist from the venom of the Chinese bird-eating spider Selenocosmia huwena , 2013, Peptides.

[41]  Xiao Mei Zheng,et al.  Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain. , 2011, Journal of medicinal chemistry.

[42]  H. Fozzard,et al.  A structural model of the tetrodotoxin and saxitoxin binding site of the Na+ channel. , 1994, Biophysical journal.

[43]  A. Wickenden,et al.  Sodium channel inhibitor drug discovery using automated high throughput electrophysiology platforms. , 2009, Combinatorial chemistry & high throughput screening.

[44]  J. W. Wolfe,et al.  Local anesthetic systemic toxicity: update on mechanisms and treatment , 2011, Current opinion in anaesthesiology.